Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD17 Intermediate Stage Hodgkin Lymphoma PET-Adapted First-Line Therapy Optimization
2007-005920-34Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Jun 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine and 4 more in Hodgkin lymphoma (HL), sponsored by University of Cologne. Started Jun 2011; status: completed.
02
Drugs
bleomycinetoposidedoxorubicincyclophosphamidevincristine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2007-005920-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005920-34.